Cargando…

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism

INTRODUCTION: Evocalcet is an oral calcimimetic agent with proven efficacy and safety in treating secondary hyperparathyroidism (SHPT) in Japanese patients on dialysis. METHODS: This randomized, double-blind, intrapatient dose-adjustment, parallel-group, international multicenter study compared the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ni, Zhaohui, Liang, Xinling, Wu, Chia-Chao, Jin, Kyubok, Kim, Yong-Lim, Lu, Kuo-Cheng, Chan, Tak Mao, Fukagawa, Masafumi, Kinoshita, Jun, Nagai, Chisato, Kojima, Masahiro, Yu, Xueqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658267/ https://www.ncbi.nlm.nih.gov/pubmed/38025238 http://dx.doi.org/10.1016/j.ekir.2023.08.034

Ejemplares similares

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study
por: Akizawa, Tadao, et al.
Publicado: (2018)

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
por: Yokoyama, Keitaro, et al.
Publicado: (2019)

Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism
por: Tokumoto, Masanori, et al.
Publicado: (2022)

Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis
por: Shigematsu, Takashi, et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
por: Akizawa, Tadao, et al.
Publicado: (2018)

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism
por: Shigematsu, Takashi, et al.
Publicado: (2022)

Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
por: Akizawa, Tadao, et al.
Publicado: (2019)

A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic
por: Ohya, Yuichiro, et al.
Publicado: (2018)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Assessment of CYP‐Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans
por: Narushima, Kazuya, et al.
Publicado: (2018)

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan
por: Yokoyama, Keitaro, et al.
Publicado: (2020)

A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro
por: Kawata, Takehisa, et al.
Publicado: (2018)

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
por: Tsuruya, Kazuhiko, et al.
Publicado: (2019)

Chemoenzymatic Approaches to the Synthesis of the Calcimimetic Agent Cinacalcet Employing Transaminases and Ketoreductases
por: Marx, Lisa, et al.
Publicado: (2018)

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Alvarado, Luis, et al.
Publicado: (2022)

Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness
por: Karaboyas, Angelo, et al.
Publicado: (2022)

Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
por: Arenas, Maria Dolores, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)

Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism
por: Sakai, Mariko, et al.
Publicado: (2020)

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
por: Kuczera, Piotr, et al.
Publicado: (2016)

Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics
por: Cunningham, John, et al.
Publicado: (2008)

Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy
por: Frazão, João, et al.
Publicado: (2008)

Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study
por: Asada, Shinji, et al.
Publicado: (2019)

Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats
por: Hasegawa, Tomoka, et al.
Publicado: (2023)

Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Otsuka, Keiichi, et al.
Publicado: (2018)

Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism
por: van der Plas, Willemijn Y., et al.
Publicado: (2016)

Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism
por: Nakayama, Kazunori, et al.
Publicado: (2013)

Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism
por: Moyes, V. J., et al.
Publicado: (2010)

Relationship between patients’ characteristics and efficacy of calcimimetics for primary hyperparathyroidism in the elderly
por: Yamamoto, Koichiro, et al.
Publicado: (2022)

Efficacy and safety of evocalcet in treatment of secondary hyperparathyroidism in chronic kidney disease on hemodialysis patients: A protocol for a systematic review and meta-analysis
por: Xie, Jing, et al.
Publicado: (2020)

Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report
por: Conzo, Giovanni, et al.
Publicado: (2012)

The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism
por: Susantitaphong, Paweena, et al.
Publicado: (2019)

The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism
por: Ngamkam, Jaruwan, et al.
Publicado: (2021)

A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride
por: Nakamura, Hironori, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dbmrao144ljbufm6oj7gsos6hm